February 03, 2025 07:45 ET | Source: Arch Biopartners TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $57,246.57 in interest accrued up to February 1, 2025 … Read more
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research Ethics Board, through the Clinical Trials Ontario Streamlined Research Ethics Review System, has granted provincial ethics approval for the Phase II trial for LSALT peptide targeting the … Read more
TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical team at … Read more
TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 290,323 common shares priced at $1.55 per common share (the “Common Shares”) for gross proceeds of $450,000 CAD (the “Offering”). The proceeds of the … Read more
TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that was previously announced on September 26, 2024 to settle an aggregate total of $2,600,000 of principal plus accrued interest of $130,000 on four deferred convertible … Read more
September 26, 2024 08:46 ET | Source: Arch Biopartners TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to settle an aggregate total of $2,600,000 of principal plus accrued interest owing on four deferred convertible … Read more
TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The clinical team at the University of … Read more
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI) Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its unique off-target effects that block toxin uptake into the kidney tissue Arch continues to perform a Phase II trial for LSALT peptide targeting cardiac … Read more
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement disclosed in a press release July 29, 2024 (the “Offering”). Pursuant to the Offering, Arch issued 400,000 common shares priced at $1.50 per common share (the … Read more
TORONTO, July 29, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement offering of 400,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $600,000 CAD (the “Offering”). The proceeds of the … Read more